A Phase 1 Study of CPI-0610, a Small Molecule Inhibitor of BET (Bromodomain and Extra-terminal) Proteins, in Patients With Progressive Lymphoma
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 07 Feb 2018
At a glance
- Drugs CPI 0610 (Primary)
- Indications Lymphoma
- Focus Adverse reactions; First in man
- Sponsors Constellation Pharmaceuticals
- 01 Feb 2018 Status changed from recruiting to active, no longer recruiting.
- 22 Nov 2016 Planned End Date changed from 1 Nov 2016 to 1 Jul 2018.
- 22 Nov 2016 Planned primary completion date changed from 1 Sep 2016 to 1 Apr 2018.